Document is current

Article History

Received: 10 September 2024

Accepted: 17 March 2025

First Online: 19 March 2025

Declarations

:

: E.T. has received consultancy fees from Arvelle Therapeutics, Argenx, Clexio, Celegene, UCB Pharma, Eisai, Epilog, Bial, Medtronic, Everpharma, Biogen, Takeda, Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals, and Marinus; speaker fees from Arvelle Therapeutics, Bial, Biogen, Böhringer Ingelheim, Eisai, Everpharma, GSK, GW Pharmaceuticals, Hikma, Liva-Nova, Newbridge, Novartis, Sanofi, Sandoz and UCB Pharma; research funding (directly, or to his institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer, and UCB Pharma outside the submitted work. He has received grants from Austrian Science Fund (FWF), Österreichische Nationalbank, and the European Union. E.T. is the CEO of Neuroconsult Ges.m.b.H. P.W. has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Alexion, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva-Ratiopharm, Janssen-Pharmazeutika, Bristol-Myers SQUIBB and Horizon Therapeutics. T.M. received travel support, honoraria for presentations or participation on advisory boards from Biogen, BMS, Novartis, Roche, Sanofi, Merck and Teva. The remaining authors report no conflict of interest.